Colorectal cancer (CRC) disproportionately causes the second highest number of UK cancer deaths (16,600 annually) as it has the fourth highest incidence. The UK has the lowest 1- and 5-year bowel cancer survival rates among the International Cancer Benchmarking Partnership countries, the majority of patients being diagnosed at late stage (III and IV). The incidence in those aged ≤50 years is increasing (particularly in 20-29-year-olds where incidence increased by 7.9% a year from 2004 to 2016). Early-stage (I and II) bowel cancer confers 92% 5-year survival, and optimising faecal immunochemical test (FIT)-based bowel screening is vital to improve bowel cancer outcomes. An observational study found FIT-based screening programmes reduced participant bowel cancer mortality by 41%, dwarfing the 16% reduction demonstrated by guaiac faecal occult blood screening. Many GP practices are supporting bowel screening by systematically and/or opportunistically giving non-responders encouragement to participate.

Endoscopy capacity has not kept pace with demand. The advent of bowel screening, the National Institute for Health and Care Excellence’s (NICE) lowering of referral thresholds (to attain early-stage diagnosis), and infection control restrictions/workforce levels due to the pandemic have all contributed to a crisis in endoscopy capacity. This could worsen as bowel screening uptake improves and eligibility is extended to those aged 50 years at a FIT positivity threshold of 80 µHb/g over the next few years.

FIT ENDORSEMENT AND COVID-19

When NICE endorsed FIT, it was predicted that FIT could safely hone demand on colonoscopy services, identifying high-risk patients and providing them with earlier diagnosis while reassessing those at very low risk. Rollout of DG30 in the UK has been patchy and evaluation clouded by COVID-19 pathway changes. COVID-19 resulted in widespread adoption of FIT as a secondary care prioritisation tool, allocating precious endoscopy slots primarily to FIT-positive patients. This resulted in a large-scale natural experiment with very positive results. Modelling of FIT-based triage during COVID-19 concluded that it reduced mortality (attributable to presentation/diagnostic delay) by 89%.

Increasingly, we are seeing FIT being used as a rule-in test/downgrade tool for high-risk patients. In the absence of evidence-based national guidance, this can be concerning for GPs. Furthermore, despite FIT’s usefulness as a triage tool, FIT-based triage can result in delay and inefficient colorectal pathways — decisions are being deferred in the hope of receiving a FIT result; a positive FIT result, received after investigations have started, can lead to additional tests being deemed necessary.

In short, despite FIT’s considerable potential to revolutionise early diagnosis of colorectal cancer, its absence at time of 366
British Journal of General Practice, August 2022
presentation/diagnostic delay) by 89%.7 Modelling of FIT-based triage during COVID-19 concluded that it reduced mortality ... by 89%.”
bowel cancer is highest in this context.12,14 The ACGPBI/BSG guideline recommends FIT be used in rectal bleeding as whole-colon imaging (colonoscopy or computed tomography colonography) is needed for FIT-positive rectal bleeders. FIT-negative rectal bleeding is more likely to be non-bowel as FIT quantifies the degradation products of haemoglobin. Flexible sigmoidoscopy is appropriate for people with FIT-negative significant rectal bleeding.

The guidance also reassures us that, despite early publications raising concern about false-negative FIT CRCs in the presence of iron deficiency anaemia, D’Souza et al11 provide reassurance that FIT has merit in this patient group too.

FIT is less reliable at alerting [non-cancer] ‘advanced colorectal neoplasia’ (sensitivity 68.4%) and ‘serious bowel disease’, for example, inflammatory bowel disease (sensitivity 67.9%) at ≥10 μHb/g faeces.12 Therefore, for patients and their primary care teams seeking to understand and resolve symptoms, access to timely non-2-week wait/urgent suspected cancer specialist advice and/or management with appropriate additional tests must be available for those who test negative.13

CONCLUSION
In relying on FIT to determine the speed, nature, and necessity of investigation, the ACGPBI/BSG guidance strongly advocates that FIT is completed at the earliest opportunity, which is in primary care, preferably prior to referral. We need to ensure symptomatic FIT is fully established in primary care. We need to promote equity of uptake across patient demographic groups. We must understand the barriers to patient concordance and have strategies to address them. Secondary care providers need to retain alternative urgent pathways for high-risk patients who cannot, or do not, complete FIT. Understanding, through effective communication, is essential between patients and health professionals about the shared responsibility for timely investigation when FIT is recommended. Practical safety-netting guidance is needed to support FIT-negative patients in the community. Safety-netting resources are expected from the ACGPBI/BSG group shortly.11

NICE intend to update their guidance on symptomatic FIT by December 2022.15 In the meantime, we should celebrate and adopt with confidence this pre-test technology that is acceptable to most patients, prudent, and improves early detection of bowel cancer.

Mary Craig, Clinical Lead [joint] for Single Cancer Pathway Implementation, Wales Cancer Network, Cardiff; GP Cancer Lead, Aneurin Bevan University Health Board, Newport.

Jeff Turner, Clinical Lead [joint] for Single Cancer Pathway Implementation, Wales Cancer Network; Consultant Gastroenterologist, University Hospital Llandough, Cardiff.

Jared Torkington, Consultant Surgeon, University Hospital of Wales, Cardiff.

Tom Crosby, Consultant Oncologist, Velindre University NHS Trust; National Cancer Clinical Director for Wales; Clinical Lead Transforming Cancer Services, Velindre Cancer Centre, Cardiff.

Open access
This article is Open Access: CC BY 4.0 licence (https://creativecommons.org/licenses/by/4.0/).

Provenance and peer review
Commissioned; externally peer reviewed.

Competing interests
The authors have declared no competing interests.

DOI: https://doi.org/10.3399/bjgp22X720209

REFERENCES
1. Cancer Research UK. Bowel cancer statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer [accessed 8 Jul 2022].
2. Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 [ICBP SURIMARK-2]: a population-based study. Lancet Oncol 2019; 20(11): 1493–1505.
3. Vaik FE, Nieuwenburg SA, Bardou M, et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 2019; 68(10): 1803–1820.
4. Gini A, Jansen EEL, Zielonke N, et al. Impact of colorectal cancer screening on cancer-specific mortality in Europe: a systematic review. Eur J Cancer 2020; 127: 224–235.
5. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. ND12. 2021. www.nice.org.uk/guidance/ng12 [accessed 8 Jul 2022].
6. National Institute for Health and Care Excellence. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care. DG03. 2017. https://www.nice.org.uk/guidance/dg38 [accessed 8 Jul 2022].
7. Lacey L, Sud A, Jones ME, et al. Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study. Gut 2021; 70(6): 1053–1060.
8. Calanzani N, Chang A, Van Melle M, et al. Recognising colorectal cancer in primary care. Adv Ther 2021; 38(5): 2732–2746.
9. Juul JS, Homung N, Andersen B, et al. The value of using the faecal immunochemical test in general practice on patients presenting with non-alarm symptoms of colorectal cancer. Br J Cancer 2018; 119(4): 471–479.
10. Ahri CS, Burns EM, Bottle A, et al. Delays in referral from primary care worsen survival for patients with colorectal cancer: a retrospective cohort study. Br J Gen Pract 2020; DOI: https://doi.org/10.3399/bjgp20X710441.
11. D’Souza N, Delisle TG, Chen M, et al. Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study. Gut 2021; 70(6): 1130–1138.
12. Sav K, Liu C, Yu W, et al. Faecal immunochemical test to image patients with possible colorectal cancer symptoms: meta-analysis. Br J Surg 2022; 109(2): 182–190.
13. Monahan KJ, Davies MM, Abulafi M, et al. Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain & Ireland (ACGPBI) and the British Society of Gastroenterology (BSG). London: ACGPBI and BSG, 2022.
14. Hicks G, D’Souza N, Delisle TG, et al. Using the faecal immunochemistry test in patients with rectal bleeding: evidence from the NICE FIT study. Colorectal Dis 2021; 23(7): 1630–1638.
15. National Institute for Health and Care Excellence. Quantitative faecal immunochemical tests to guide colorectal cancer pathway referral for people with a change in bowel habit or abdominal pain. NG12. 2021. www.nice.org.uk/guidance/ng12 [accessed 13 Jul 2022].

ADDRESS FOR CORRESPONDENCE
Mary Craig
Cancer Services, Block 10, Royal Gwent Hospital, Cardiff Road, Newport NP20 2UB, UK.
Email: mary.craig2@wales.nhs.uk

British Journal of General Practice, August 2022